Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. / Sørensen, Per Soelberg; Bertolotto, Antonio; Edan, Gilles; Giovannoni, Gavin; Gold, Ralf; Havrdova, Eva; Kappos, Ludwig; Kieseier, Bernd C; Montalban, Xavier; Olsson, Tomas.
I: Multiple Sclerosis, Bind 18, Nr. 2, 2012, s. 143-52.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
AU - Sørensen, Per Soelberg
AU - Bertolotto, Antonio
AU - Edan, Gilles
AU - Giovannoni, Gavin
AU - Gold, Ralf
AU - Havrdova, Eva
AU - Kappos, Ludwig
AU - Kieseier, Bernd C
AU - Montalban, Xavier
AU - Olsson, Tomas
PY - 2012
Y1 - 2012
N2 - Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients with MS and use of natalizumab are provided based on the presence of these three risk factors. The identification of risk factors that increase the likelihood of PML in natalizumab-treated patients can facilitate benefit-risk discussions between health care professionals and patients. Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development.
AB - Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV). We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML. Natalizumab treatment duration and prior use of immunosuppressive therapies are established risk factors for development of PML in natalizumab-treated patients. With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV. The availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Recommendations for clinical management of patients with MS and use of natalizumab are provided based on the presence of these three risk factors. The identification of risk factors that increase the likelihood of PML in natalizumab-treated patients can facilitate benefit-risk discussions between health care professionals and patients. Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development.
U2 - 10.1177/1352458511435105
DO - 10.1177/1352458511435105
M3 - Journal article
VL - 18
SP - 143
EP - 152
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 2
ER -
ID: 48584491